Centogene N.V. (CNTG)

Market Cap	34.39M
Revenue (ttm)	99.60M
Net Income (ttm)	-52.57M
Shares Out	27.08M
EPS (ttm)	-2.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,404
Open	1.34
Previous Close	1.29
Day's Range	1.26 - 1.35
52-Week Range	0.68 - 5.18
Beta	-1.08
Analysts	Buy
Price Target	2.55 (+100.79%)
Earnings Date	Mar 28, 2023

About CNTG

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 7, 2019
• Employees: 808
• Stock Exchange: NASDAQ
• Ticker Symbol: CNTG

Financial Performance

In 2021, Centogene's revenue was 189.92 million, an increase of 47.94% compared to the previous year's 128.38 million. Losses were -46.41 million, 116.0% more than in 2020.

Financial numbers in EUR

Analyst Forecast

According to 7 analysts, the average rating for CNTG stock is "Buy." The 12-month stock price forecast is $2.55, which is an increase of 100.79% from the latest price.

Price Target

$2.55

(100.79% upside)

Analyst Consensus: Buy